Teva Pharmaceutical Industries (NYSE:TEVA) is in focus after the U.S. FDA accepted its New Drug Application for ecopipam, a potential first-in-class treatment for pediatric Tourette syndrome with Orphan Drug and Priority Review status. At a share price of US$36.19, Teva Pharmaceutical Industries has a 1-year total shareholder return of 93.01% and a 5-year total shareholder return of 282.96%. This suggests strong long-term momentum, even after a recent 5.01% decline in the 7-day share price...

TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries L

Teva Pharmaceutical Industries · Last Price36.05 · Market Cap41.8B · Open36.17 · High36.3347 · Low35.62 · Year High38.37 · Previous Close36.44 · EPS (TTM)0.43

Teva Pharmaceutical Industries has agreed to serve as the stalking horse bidder for certain BioXcel Therapeutics assets in a bankruptcy…

See the latest TEVA/USD price and convert Teva Pharmaceutical Industries Limited to United States Dollar with our instant converter. 1 TEVA is currently worth 36.30 USD.

See the latest TEVA/CAD price and convert Teva Pharmaceutical Industries Limited to Canadian Dollar with our instant converter. 1 TEVA is currently worth 49.91 CAD.